Revenue
0 USD
2021 Q2 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Fundies. English
China Botanic Pharmaceutical
EDGAR113 filing records in this dataset, filed from 1996-07-24 to 2025-09-11. Reported financial figures are available; chart coverage varies by period.
Latest quarter
- Cash and cash equivalents
- 633 USD Source
Exact value
633 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 21.5 million shares Source
Exact value
21453078 shares
Reported share-count change
12.38% · 2.36 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-158 thousand USD
2024-08-01 – 2025-07-31
Exact inputs and evidence
- Operating cash flow: -423366 USD · 2023-11-01 – 2024-10-31 Source
- Operating cash flow: -385735 USD · 2023-11-01 – 2024-07-31 Source
- Operating cash flow: -76990 USD · 2024-11-01 – 2025-01-31 Source
- Operating cash flow: -93522 USD · 2024-11-01 – 2025-04-30 Source
- Operating cash flow: -76990 USD · 2024-11-01 – 2025-01-31 Source
- Operating cash flow: -119956 USD · 2024-11-01 – 2025-07-31 Source
- Operating cash flow: -93522 USD · 2024-11-01 – 2025-04-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2025-09-11.
Financial data available through: 2024-10-31.
Coverage by financial measure
- Revenue: 1 of 11 periods available· newest 2020-10-31
- Operating income: 5 of 11 periods available· newest 2024-10-31
- Net income: 5 of 11 periods available· newest 2024-10-31
- Operating cash flow: 5 of 11 periods available· newest 2024-10-31
- capital expenditure: No compatible figures in this window
- Total assets: 4 of 11 periods available· newest 2024-10-31
- Total liabilities: 5 of 11 periods available· newest 2024-10-31
- Current assets: 1 of 11 periods available· newest 2022-10-31
- Current liabilities: 5 of 11 periods available· newest 2024-10-31
- Cash and cash equivalents: 5 of 11 periods available· newest 2024-10-31
- long term debt: No compatible figures in this window
- Shares outstanding: 5 of 11 periods available· newest 2024-10-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 2.25 millionPrior period
−USD 505,197
–
Current period
−USD 2.76 million
–
Exact inputs and evidence
-2755404 − -505197 = -2250207 USD
-505197 USD · 2022-11-01 – 2023-10-31
Inspect prior input Prior source-2755404 USD · 2023-11-01 – 2024-10-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 323,751Prior period
−USD 99,615
–
Current period
−USD 423,366
–
Exact inputs and evidence
-423366 − -99615 = -323751 USD
-99615 USD · 2022-11-01 – 2023-10-31
Inspect prior input Prior source-423366 USD · 2023-11-01 – 2024-10-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2020 2019-11-01 – 2020-10-31
- Revenue USD 0
- Operating costs Derived USD 0
- Operating income USD 0
- Tax, interest and other Derived USD 0
- Net income USD 0
Cash
- Operating cash flow USD 0
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2020 Not shown: operating income or net income is not reported.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2020 2019-11-01 – 2020-10-31 | 0 | 0 Derived | 0 | 0 Derived | 0 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 0 2020
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2020 | Revenue | 0 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020 | Operating margin | Not reported |
|
| 2020 | Net margin | Not reported |
|
| 2020 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD 0 2020
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2020 | Operating cash flow | 0 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2020 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020 | Liabilities / assets | Not reported |
|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020-10-31 | Current assets / current liabilities | Not reported |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2020 2019-11-01 – 2020-10-31 | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2020-11-01 – 2021-10-31 | −USD 325,088 Exact valueExact value: -325088 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 75,088 Exact valueExact value: -75088 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2021-11-01 – 2022-10-31 | −USD 107,411 Exact valueExact value: -107411 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 106,366 Exact valueExact value: -106366 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2022-11-01 – 2023-10-31 | −USD 505,197 Exact valueExact value: -505197 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 99,615 Exact valueExact value: -99615 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2023-11-01 – 2024-10-31 | −USD 2.76 million Exact valueExact value: -2755404 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 423,366 Exact valueExact value: -423366 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
113 filings · 1,170 latest values · 1,170 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0000926844, 926844, cbp, edgar:926844
Also known as ANZA CAPITAL INC, CHINA BOTANIC PHARMACEUTICAL INC., COMTECH CONSOLIDATION GROUP INC, China Botanic Pharmaceutical, E NET CORP, E NET CORP/NV, E NET FINANCIAL CORP, E-NET COM CORP, E-NET FINANCIAL COM CORP, FUSS BRANDS CORP., Fuss Brands Corp., RENHUANG PHARMACEUTICALS INC, SOLUTIONS INC, SUARRO COMMUNICATIONS INC